Kamada (KMDA) Misses Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Kamada Reports Third Quarter 2015 Financial Results
November 10, 2015 7:01 AM ESTReaffirms FY 2015 revenue guidance of $70-73 million
Conference call begins today at 8:30 a.m. Eastern time
NESS ZIONA, Israel--(BUSINESS WIRE)-- Kamada Ltd. (NASDAQ: KMDA) (TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces financial results for the three and nine months ended September 30, 2015.
Financial highlights of the 2015 third quarter included:
Total revenues of $16.1 million compared with $17.2 million for the third quarter of 2014; Proprietary product revenue of $9.6 million compared with $9.1 million in... More